JP7847576B2 - がんの治療のための組み合わせ - Google Patents

がんの治療のための組み合わせ

Info

Publication number
JP7847576B2
JP7847576B2 JP2023506226A JP2023506226A JP7847576B2 JP 7847576 B2 JP7847576 B2 JP 7847576B2 JP 2023506226 A JP2023506226 A JP 2023506226A JP 2023506226 A JP2023506226 A JP 2023506226A JP 7847576 B2 JP7847576 B2 JP 7847576B2
Authority
JP
Japan
Prior art keywords
compound
cancer
approximately
cell
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023506226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536264A (ja
JP2023536264A5 (enExample
Inventor
ギセラ シュワブ，
クリスティアン シェフォルド，
コリン チョン，
スーチェン ジェフ スー，
ピーター ラム，
ペイウェン ユー，
Original Assignee
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2023536264A publication Critical patent/JP2023536264A/ja
Publication of JP2023536264A5 publication Critical patent/JP2023536264A5/ja
Application granted granted Critical
Publication of JP7847576B2 publication Critical patent/JP7847576B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023506226A 2020-07-31 2021-07-29 がんの治療のための組み合わせ Active JP7847576B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063059601P 2020-07-31 2020-07-31
US63/059,601 2020-07-31
US202063113556P 2020-11-13 2020-11-13
US63/113,556 2020-11-13
US202163148921P 2021-02-12 2021-02-12
US63/148,921 2021-02-12
PCT/US2021/043699 WO2022026706A1 (en) 2020-07-31 2021-07-29 Combinations for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2023536264A JP2023536264A (ja) 2023-08-24
JP2023536264A5 JP2023536264A5 (enExample) 2024-08-05
JP7847576B2 true JP7847576B2 (ja) 2026-04-17

Family

ID=77431400

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023506226A Active JP7847576B2 (ja) 2020-07-31 2021-07-29 がんの治療のための組み合わせ

Country Status (18)

Country Link
US (1) US20230301979A1 (enExample)
EP (1) EP4188376A1 (enExample)
JP (1) JP7847576B2 (enExample)
KR (1) KR20230059792A (enExample)
CN (1) CN116437954A (enExample)
AU (1) AU2021318134A1 (enExample)
BR (1) BR112023001792A2 (enExample)
CA (1) CA3186517A1 (enExample)
CL (1) CL2023000289A1 (enExample)
CO (1) CO2023001561A2 (enExample)
CR (1) CR20230052A (enExample)
GE (1) GEAP202616896A (enExample)
IL (1) IL300151A (enExample)
MX (1) MX2023001298A (enExample)
PE (1) PE20231369A1 (enExample)
PH (1) PH12023550160A1 (enExample)
TW (1) TW202220654A (enExample)
WO (1) WO2022026706A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202415420A (en) * 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
US20230326575A1 (en) * 2020-04-29 2023-10-12 Societe Des Produits Nestle S.A. System and method for providing fertility enhancing dietary recommendations in individuals with low testosterone
WO2021219579A1 (en) * 2020-04-29 2021-11-04 Société des Produits Nestlé S.A. System and method for providing fertility enhancing dietary recommendations in individuals with sperm conditions
JP2025509343A (ja) * 2022-03-07 2025-04-11 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の治療のための他の薬剤と組み合わせたイサツキシマブの使用
EP4504264A4 (en) * 2022-04-08 2026-03-11 Global Cancer Tech Inc METHODS AND PRODUCTS FOR SCREENING AND TREATMENT OF GLIOBLASTOMA MULTIFORME AND OTHER CANCERS, INCLUDING BREAST CANCERS, USING A COMBINATION OF PI3KINASE INHIBITORS WITH CHECKPOINT INHIBITORS
CN120390641A (zh) * 2022-10-19 2025-07-29 西雅图儿童医院（Dba西雅图儿童研究所） 采用靶向小分子和抗靶向car t细胞的治疗方法
EP4665766A2 (en) * 2023-02-13 2025-12-24 LAVA Therapeutics N.V. Combination therapy comprising multispecific gamma delta tcr antibodies
EP4450972A1 (en) * 2023-04-21 2024-10-23 Fundación Instituto de Investigación Sanitaria de Santiago de Compostela In vitro method for predicting cancer patient response to pd-1 and/or pd-l1 inhibitors
CN117285533B (zh) * 2023-11-24 2024-01-30 四川省医学科学院·四川省人民医院 CD47/SIRPα小分子抑制剂及其应用和抗肿瘤药物组合物
KR20260016691A (ko) * 2024-07-25 2026-02-04 서울대학교산학협력단 Tpst2 억제제 또는 ifngr1의 황산화 억제제를 포함하는 암의 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019148044A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
JP2019529476A (ja) 2016-09-27 2019-10-17 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法
JP2020514311A (ja) 2017-01-20 2020-05-21 エグゼリクシス， インコーポレイテッド がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ
WO2020123800A1 (en) 2018-12-13 2020-06-18 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019529476A (ja) 2016-09-27 2019-10-17 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法
JP2020514311A (ja) 2017-01-20 2020-05-21 エグゼリクシス， インコーポレイテッド がんを治療するためのカボザンチニブとアテゾリズマブの組み合わせ
WO2019148044A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2020123800A1 (en) 2018-12-13 2020-06-18 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Annals of Oncology，2017年，Vol.28，Suppl.5, p.309

Also Published As

Publication number Publication date
IL300151A (en) 2023-03-01
WO2022026706A1 (en) 2022-02-03
US20230301979A1 (en) 2023-09-28
MX2023001298A (es) 2023-02-22
PH12023550160A1 (en) 2023-09-18
CL2023000289A1 (es) 2023-09-01
BR112023001792A2 (pt) 2023-04-11
CO2023001561A2 (es) 2023-02-16
CA3186517A1 (en) 2022-02-03
JP2023536264A (ja) 2023-08-24
AU2021318134A1 (en) 2023-03-02
TW202220654A (zh) 2022-06-01
KR20230059792A (ko) 2023-05-03
CR20230052A (es) 2023-04-11
EP4188376A1 (en) 2023-06-07
GEAP202616896A (en) 2026-04-27
CN116437954A (zh) 2023-07-14
PE20231369A1 (es) 2023-09-07

Similar Documents

Publication Publication Date Title
US20230301979A1 (en) Combinations for the treatment of cancer
JP7783870B2 (ja) キナーゼ阻害剤の結晶性形態及び塩形態
EP3976587B1 (en) Crystalline salt forms of a kinase inhibitor
US20250368606A1 (en) Crystalline forms and salt forms of a kinase inhibitor
HK40067664B (zh) 激酶抑制剂的结晶盐形式
HK40060502A (en) Crystalline forms and salt forms of a kinase inhibitor
HK40067664A (en) Crystalline salt forms of a kinase inhibitor
HK40061293B (en) Crystalline forms and salt forms of a kinase inhibitor
HK40061293A (en) Crystalline forms and salt forms of a kinase inhibitor
EA048718B1 (ru) Кристаллические солевые формы ингибитора киназы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260407

R150 Certificate of patent or registration of utility model

Ref document number: 7847576

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150